Central Nervous System
Central nervous system (CNS) diseases, including schizophrenia or Alzheimer’s disease, are a focus of Boehringer Ingelheim discovery research and development. We have a range of different compounds in development, some in advanced clinical phases. We specifically address cognitive impairment a problem across many neuropsychiatric diseases.
Together with our research activity in other fields of psychiatry, including treatmentresistant depression and “beyond the pill” approaches, it represents our mission to develop effective innovative treatment approaches for these underserved illnesses.
-
Central Nervous System
Dr. Jan Poth, Therapeutic Area Head Central Nervous System
-
Prevention of Schizophrenia
Central Nervous System
That’s what investigators are hoping to find out. Read about latest research in the field
-
-
-
-
Central Nervous System Diseases (CNS)
Boehringer Ingelheim and Domain Therapeutics sign a multi-target research collaboration and license agreement on GPCRs for CNS Disorders
-
-
World Mental Health Day 2018
-
DOWNLOAD PDF (7.3 MB)
Facts and stats on Alzheimer’s disease.
-
Our Commitment Never Stops
Disease Focus
Brain research is challenging, but despite potential setbacks, we persist in our learning to find effective solutions.
-
Michael Sand’s personal perspective on CNS research
Central Nervous System
Meet BI’s Brains: Michael Sand’s personal perspective on CNS research
-
-
Randye's Story
Central Nervous System Diseases (CNS)
Randye Kaye shares her experiences of being a mother of a son who has schizophrenia
-
-
DOWNLOAD PDF (503.55 KB)
Snapshots from people we know living with Alzheimer’s
-
DOWNLOAD PDF (2.25 MB)
Why we are bringing a fresh-thinking approach to CNS research
-
Research & Development